Kura Oncology and The Leukemia & Lymphoma Society announced a clinical collaboration to evaluate Kura‘s menin inhibitor, ziftomenib, in combination with chemotherapy in pediatric patients with relapsed/refractory KMT2A-rearranged, NUP98-rearranged or NPM1-mutant acute leukemia. In partnership with the PedAL Initiative, LLS will serve as the coordinating sponsor in North America and the Princess Maxima Center for Pediatric Oncology in Utrecht, the Netherlands, will serve as the coordinating sponsor in Europe. PedAL is a pioneering global master clinical trial for Pediatric Acute Leukemia, founded and led by LLS, which aims to advance more effective, safer treatments with fewer long-term side effects, for children with blood cancer. Under the terms of the agreement, LLS and the Princess Maxima Center will sponsor the Phase 1 study of ziftomenib in pediatric patients with acute leukemias. Kura will supply LLS and the Princess Maxima Center with ziftomenib for the study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KURA:
- Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit
- Oppenheimer biotechnology analyst to hold an analyst/industry conference call
- Kura Oncology price target lowered to $37 from $40 at Wedbush
- Kura Oncology price target lowered to $30 from $47 at Barclays
- Kura Oncology files automatic mixed securities shelf